Private Companies Among Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 5.1% Last Week
Private Companies Among Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 5.1% Last Week
Key Insights
关键见解
- Significant control over Betta Pharmaceuticals by private companies implies that the general public has more power to influence management and governance-related decisions
- 50% of the business is held by the top 9 shareholders
- Institutions own 16% of Betta Pharmaceuticals
- 私营公司对Betta Pharmicals的严格控制意味着公众拥有更大的影响管理和治理相关决策的权力
- 50% 的业务由前9名股东持有
- 机构拥有贝塔制药16%的股份
Every investor in Betta Pharmaceuticals Co., Ltd. (SZSE:300558) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 41% to be precise, is private companies. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
贝达制药有限公司(深圳证券交易所代码:300558)的每位投资者都应该了解最强大的股东群体。持有该公司股份最多的集团是私营公司,准确地说约为41%。也就是说,如果股票上涨,该集团将受益最大(如果股价下跌,则损失最大)。
As a result, private companies were the biggest beneficiaries of last week's 5.1% gain.
结果,私营公司是上周5.1%涨幅的最大受益者。
Let's take a closer look to see what the different types of shareholders can tell us about Betta Pharmaceuticals.
让我们仔细看看不同类型的股东能告诉我们有关贝塔制药的哪些信息。
What Does The Institutional Ownership Tell Us About Betta Pharmaceuticals?
关于贝塔制药,机构所有权告诉我们什么?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
许多机构根据近似于当地市场的指数来衡量自己的表现。因此,他们通常会更多地关注主要指数中包含的公司。
We can see that Betta Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Betta Pharmaceuticals' historic earnings and revenue below, but keep in mind there's always more to the story.
我们可以看到,贝塔制药确实有机构投资者;他们持有该公司很大一部分股票。这表明专业投资者有一定的信誉。但是我们不能仅仅依靠这个事实,因为机构有时会像所有人一样进行不良投资。当多家机构拥有一只股票时,总是存在处于 “拥挤交易” 的风险。当这样的交易出错时,多方可能会竞相快速出售股票。对于没有增长历史的公司,这种风险更高。你可以在下面看到Betta Pharmaceuticals的历史收益和收入,但请记住,故事总是有更多内容。
Hedge funds don't have many shares in Betta Pharmaceuticals. Ningbo Kaiming Investment Management Partnership Enterprise (Limited Partnership) is currently the company's largest shareholder with 19% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 13% and 6.9%, of the shares outstanding, respectively.
对冲基金在贝达制药的股票不多。宁波开明投资管理合伙企业(有限合伙)目前是公司的最大股东,已发行股份的19%。同时,第二和第三大股东分别持有已发行股份的13%和6.9%。
We also observed that the top 9 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.
我们还观察到,前9名股东占股票登记册的一半以上,少数规模较小的股东可以在一定程度上平衡大股东的利益。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.
虽然研究公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向哪个方向吹来也是有意义的。有不少分析师报道了该股,因此你可以很容易地研究预测的增长。
Insider Ownership Of Betta Pharmaceuticals
贝塔制药的内部所有权
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
公司内部人员的定义可能是主观的,并且在不同的司法管辖区之间确实有所不同。我们的数据反映了个人内部人士,至少涵盖了董事会成员。公司管理层经营业务,但首席执行官将对董事会负责,即使他或她是董事会成员。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
当内部所有权表明领导层像公司的真正所有者一样思考时,内部所有权是积极的。但是,高度的内部所有权也可以赋予公司内部的一小部分人巨大的权力。在某些情况下,这可能是负面的。
We can report that insiders do own shares in Betta Pharmaceuticals Co., Ltd.. The insiders have a meaningful stake worth CN¥691m. Most would see this as a real positive. Most would say this shows alignment of interests between shareholders and the board. Still, it might be worth checking if those insiders have been selling.
我们可以报告说,内部人士确实拥有贝达制药有限公司的股份。内部人士持有价值6.91亿元人民币的大量股份。大多数人会认为这是一个真正的积极因素。大多数人会说,这表明股东和董事会之间的利益一致。尽管如此,可能值得检查一下这些内部人士是否一直在出售。
General Public Ownership
一般公有制
With a 39% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Betta Pharmaceuticals. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Betta Pharmicals拥有39%的所有权,主要由个人投资者组成的公众对贝塔制药有一定程度的影响力。这种所有权规模虽然可观,但如果决策与其他大股东不同步,可能不足以改变公司政策。
Private Company Ownership
私人公司所有权
Our data indicates that Private Companies hold 41%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
我们的数据显示,私营公司持有公司41%的股份。私营公司可能是关联方。有时,内部人士通过控股私营公司而对上市公司拥有权益,而不是以个人身份拥有权益。尽管很难得出任何宽泛的结论,但值得注意的是,这是一个需要进一步研究的领域。
Next Steps:
后续步骤:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Betta Pharmaceuticals , and understanding them should be part of your investment process.
尽管值得考虑拥有公司的不同群体,但还有其他因素更为重要。例如,以永远存在的投资风险幽灵为例。我们已经向Betta Pharmicals发现了一个警告信号,了解它们应该是您投资过程的一部分。
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
但归根结底,决定这家企业所有者的表现的是未来,而不是过去。因此,我们认为最好看一下这份免费报告,该报告显示了分析师是否预测了更光明的未来。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。